Johnson & Johnson Price to Book Ratio 2012-2025 | JNJ
Historical price to book ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current price to book ratio for Johnson & Johnson as of March 06, 2026 is 7.19.
| Johnson & Johnson Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-03-06 | 240.40 | 7.10 | |
| 2025-12-31 | 205.86 | $33.86 | 6.08 |
| 2025-09-30 | 183.28 | $32.95 | 5.56 |
| 2025-06-30 | 149.88 | $32.61 | 4.60 |
| 2025-03-31 | 161.35 | $32.47 | 4.97 |
| 2024-12-31 | 139.59 | $29.70 | 4.70 |
| 2024-09-30 | 155.17 | $29.14 | 5.32 |
| 2024-06-30 | 138.89 | $29.72 | 4.67 |
| 2024-03-31 | 149.12 | $29.09 | 5.13 |
| 2023-12-31 | 146.64 | $28.57 | 5.13 |
| 2023-09-30 | 144.56 | $29.59 | 4.89 |
| 2023-06-30 | 152.52 | $29.41 | 5.19 |
| 2023-03-31 | 141.75 | $27.27 | 5.20 |
| 2022-12-31 | 160.40 | $29.39 | 5.46 |
| 2022-09-30 | 147.38 | $28.51 | 5.17 |
| 2022-06-30 | 159.08 | $29.04 | 5.48 |
| 2022-03-31 | 157.81 | $28.41 | 5.55 |
| 2021-12-31 | 151.36 | $28.16 | 5.38 |
| 2021-09-30 | 141.96 | $26.69 | 5.32 |
| 2021-06-30 | 143.95 | $26.44 | 5.45 |
| 2021-03-31 | 142.72 | $25.01 | 5.71 |
| 2020-12-31 | 135.82 | $24.04 | 5.65 |
| 2020-09-30 | 127.60 | $24.49 | 5.21 |
| 2020-06-30 | 119.73 | $23.92 | 5.00 |
| 2020-03-31 | 110.88 | $23.28 | 4.76 |
| 2019-12-31 | 122.56 | $22.59 | 5.43 |
| 2019-09-30 | 107.95 | $22.13 | 4.88 |
| 2019-06-30 | 115.35 | $23.01 | 5.01 |
| 2019-03-31 | 114.99 | $22.20 | 5.18 |
| 2018-12-31 | 105.45 | $22.44 | 4.70 |
| 2018-09-30 | 112.19 | $24.09 | 4.66 |
| 2018-06-30 | 97.87 | $23.45 | 4.17 |
| 2018-03-31 | 102.60 | $23.58 | 4.35 |
| 2017-12-31 | 111.16 | $22.43 | 4.96 |
| 2017-09-30 | 102.80 | $27.55 | 3.73 |
| 2017-06-30 | 103.94 | $26.78 | 3.88 |
| 2017-03-31 | 97.22 | $26.10 | 3.72 |
| 2016-12-31 | 89.34 | $26.02 | 3.43 |
| 2016-09-30 | 90.97 | $26.73 | 3.40 |
| 2016-06-30 | 92.79 | $26.47 | 3.51 |
| 2016-03-31 | 82.19 | $26.40 | 3.11 |
| 2015-12-31 | 77.46 | $25.82 | 3.00 |
| 2015-09-30 | 69.88 | $25.86 | 2.70 |
| 2015-06-30 | 72.40 | $25.69 | 2.82 |
| 2015-03-31 | 74.19 | $24.45 | 3.03 |
| 2014-12-31 | 76.59 | $25.06 | 3.06 |
| 2014-09-30 | 77.56 | $27.31 | 2.84 |
| 2014-06-30 | 75.62 | $27.65 | 2.73 |
| 2014-03-31 | 70.51 | $27.08 | 2.60 |
| 2013-12-31 | 65.27 | $26.25 | 2.49 |
| 2013-09-30 | 61.35 | $24.75 | 2.48 |
| 2013-06-30 | 60.31 | $24.75 | 2.44 |
| 2013-03-31 | 56.84 | $23.85 | 2.38 |
| 2012-12-31 | 48.48 | $23.33 | 2.08 |
| 2012-09-30 | 47.24 | $23.08 | 2.05 |
| 2012-06-30 | 45.90 | $21.97 | 2.09 |
| 2012-03-31 | 44.38 | $22.35 | 1.99 |
| 2011-12-31 | 43.74 | $20.95 | 2.09 |
| 2011-09-30 | 42.09 | $22.52 | 1.87 |
| 2011-06-30 | 43.57 | $22.67 | 1.92 |
| 2011-03-31 | 38.47 | $21.86 | 1.76 |
| 2010-12-31 | 39.80 | $20.66 | 1.93 |
| 2010-09-30 | 39.53 | $20.85 | 1.90 |
| 2010-06-30 | 37.33 | $19.19 | 1.95 |
| 2010-03-31 | 40.84 | $19.19 | 2.13 |
| 2009-12-31 | 40.04 | $18.37 | 2.18 |
| 2009-09-30 | 37.55 | $18.27 | 2.06 |
| 2009-06-30 | 34.75 | $16.79 | 2.07 |
| 2009-03-31 | 31.90 | $15.87 | 2.01 |
| 2008-12-31 | 35.98 | $15.35 | 2.34 |
| 2008-09-30 | 41.32 | $16.45 | 2.51 |
| 2008-06-30 | 38.13 | $16.61 | 2.30 |
| 2008-03-31 | 38.17 | $16.19 | 2.36 |
| 2007-12-31 | 38.99 | $15.25 | 2.56 |
| 2007-09-30 | 38.17 | $15.17 | 2.52 |
| 2007-06-30 | 35.56 | $14.90 | 2.39 |
| 2007-03-31 | 34.55 | $14.14 | 2.44 |
| 2006-12-31 | 37.63 | $13.59 | 2.77 |
| 2006-09-30 | 36.81 | $13.97 | 2.63 |
| 2006-06-30 | 33.77 | $13.89 | 2.43 |
| 2006-03-31 | 33.17 | $13.83 | 2.40 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $586.690B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.092B | 42.96 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.53 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Pfizer (PFE) | United States | $156.812B | 8.54 |
| Sanofi (SNY) | France | $112.219B | 10.39 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |
| Innoviva (INVA) | United States | $1.697B | 8.50 |